Genetics, transcriptomics, and proteomics of Alzheimer's disease.

OBJECTIVE To provide an updated overview of the methods used in genetic, transcriptomic, and proteomic studies in Alzheimer's disease and to demonstrate the importance of those methods for the improvement of the current diagnostic and therapeutic possibilities. DATA SOURCES MEDLINE-based search of 233 peer-reviewed articles published between 1975 and 2006. DATA SYNTHESIS Alzheimer's disease is a genetically heterogeneous disorder. Rare mutations in the amyloid precursor protein, presenilin 1, and presenilin 2 genes have shown the importance of the amyloid metabolism for its development. In addition, converging evidence from population-based genetic studies, gene expression studies, and protein profile studies in the brain and in the cerebrospinal fluid suggest the existence of several pathogenetic pathways such as amyloid precursor protein processing, beta-amyloid degradation, tau phosphorylation, proteolysis, protein misfolding, neuroinflammation, oxidative stress, and lipid metabolism. CONCLUSIONS The development of high-throughput genotyping methods and of elaborated statistical analyses will contribute to the identification of genetic risk profiles related to the development and course of this devastating disease. The integration of knowledge derived from genetic, transcriptomic, and proteomic studies will greatly advance our understanding of the causes of Alzheimer's disease, improve our capability of establishing an early diagnosis, help define disease subgroups, and ultimately help to pave the road toward improved and tailored treatments.

[1]  Kevin M. Brown,et al.  Gene expression correlates of neurofibrillary tangles in Alzheimer's disease , 2006, Neurobiology of Aging.

[2]  D. Bozyczko‐Coyne,et al.  Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease , 2006, Neurobiology of Aging.

[3]  F. Jessen,et al.  APOA1 polymorphism influences risk for early‐onset nonfamiliar AD , 2005, Annals of neurology.

[4]  Andreas Papassotiropoulos,et al.  A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. , 2005, The Journal of clinical psychiatry.

[5]  G. Alexander,et al.  Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism , 2005 .

[6]  Jürgen Götz,et al.  Functional Genomics meets neurodegenerative disorders Part II: Application and data integration , 2005, Progress in Neurobiology.

[7]  J. Götz,et al.  Functional Genomics meets neurodegenerative disorders Part I: Transcriptomic and proteomic technology , 2005, Progress in Neurobiology.

[8]  P. Zuo,et al.  Gene expression profile of amyloid beta protein-injected mouse model for Alzheimer disease , 2005, Acta Pharmacologica Sinica.

[9]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[10]  P. Steinlein,et al.  Phosphoproteome and transcriptome analysis of the neuronal response to a CDK5 inhibitor , 2005, Proteomics.

[11]  D. Blacker,et al.  Family-based association between Alzheimer's disease and variants in UBQLN1. , 2005, The New England journal of medicine.

[12]  K. Mirnics,et al.  Presenilin-1-Dependent Transcriptome Changes , 2005, The Journal of Neuroscience.

[13]  Kewei Chen,et al.  Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Green,et al.  Genetic susceptibility testing versus family history–based risk assessment: Impact on perceived risk of Alzheimer disease , 2005, Genetics in Medicine.

[15]  I. Ferrer,et al.  Familial Alzheimer disease associated with A713T mutation in APP , 2004, Neuroscience Letters.

[16]  Nick C Fox,et al.  A presenilin 1 R278I mutation presenting with language impairment , 2004, Neurology.

[17]  Richard D. Kim,et al.  Reduced β-Amyloid Production and Increased Inflammatory Responses in Presenilin Conditional Knock-out Mice* , 2004, Journal of Biological Chemistry.

[18]  H. Mori,et al.  A novel presenilin-1 mutation (Leu85Pro) in early-onset Alzheimer disease with spastic paraparesis. , 2004, Archives of neurology.

[19]  M. Barquero,et al.  New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism , 2004, European journal of neurology.

[20]  K. Nakashima,et al.  A novel presenilin 1 mutation (Y154N) in a patient with early onset Alzheimer's disease with spastic paraparesis , 2004, Neuroscience Letters.

[21]  A. Bizzi,et al.  A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene , 2004, Neurology.

[22]  Junmin Peng,et al.  Proteomic Characterization of Postmortem Amyloid Plaques Isolated by Laser Capture Microdissection*[boxs] , 2004, Journal of Biological Chemistry.

[23]  V. La Bella,et al.  A novel mutation (Thr116Ile) in the presenilin 1 gene in a patient with early‐onset Alzheimer's disease , 2004, European journal of neurology.

[24]  J. Hardy,et al.  A new presenilin Alzheimer’s disease case confirms the helical alignment of pathogenic mutations in transmembrane domain 5 , 2004, Neuroscience Letters.

[25]  M. Fountoulakis,et al.  Application of proteomics technologies in the investigation of the brain. , 2004, Mass spectrometry reviews.

[26]  R. Green,et al.  Estimating risk curves for first-degree relatives of patients with Alzheimer’s disease: The REVEAL study , 2004, Genetics in Medicine.

[27]  T. Iwatsubo,et al.  Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[28]  E. Rogaev,et al.  Role for glyoxalase I in Alzheimer's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  C. van Broeckhoven,et al.  A novel presenilin 1 mutation associated with Pick's disease but not β‐amyloid plaques , 2004, Annals of neurology.

[30]  Yanbin Jia,et al.  Association study of an SNP combination pattern in the dopaminergic pathway in paranoid schizophrenia: a novel strategy for complex disorders , 2004, Molecular Psychiatry.

[31]  B. Strooper,et al.  Presenilins in Memory, Alzheimer's Disease, and Therapy , 2004, Neuron.

[32]  D. Butterfield.  Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain , 2004, Brain Research.

[33]  E. Mufson,et al.  Gene Expression Profiles of Cholinergic Nucleus Basalis Neurons in Alzheimer's Disease , 2002, Neurochemical Research.

[34]  S. Shimohama,et al.  Proteomic Profiling and Neurodegeneration in Alzheimer's Disease , 2002, Neurochemical Research.

[35]  J. Klose.  Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues , 1975, Humangenetik.

[36]  Richard D. Kim,et al.  Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. , 2004, The Journal of biological chemistry.

[37]  J. Wegiel,et al.  A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (Pro117Ser): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations. , 2004, Journal of Alzheimer's disease : JAD.

[38]  W. Kozubski,et al.  Presenilin 1 mutations in Polish families with early-onset Alzheimer's disease. , 2004, Folia neuropathologica.

[39]  A. Pfeffer,et al.  Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland , 2003, Experimental Neurology.

[40]  Sandro Sorbi,et al.  Identification of new presenilin gene mutations in early-onset familial Alzheimer disease. , 2003, Archives of neurology.

[41]  Claudio Franceschi,et al.  Interleukin-6 gene alleles affect the risk of Alzheimer’s disease and levels of the cytokine in blood and brain , 2003, Neurobiology of Aging.

[42]  Kaj Blennow,et al.  Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. , 2003, Brain research. Molecular brain research.

[43]  R. Martins,et al.  Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer’s disease , 2003, Neurobiology of Aging.

[44]  D. Butterfield,et al.  Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration , 2003, Journal of neurochemistry.

[45]  Visith Thongboonkerd,et al.  Proteomic identification of nitrated proteins in Alzheimer's disease brain , 2003, Journal of neurochemistry.

[46]  J. Kira,et al.  A novel mutation (L250V) in the presenilin 1 gene in a Japanese familial Alzheimer's disease with myoclonus and generalized convulsion , 2003, Journal of the Neurological Sciences.

[47]  I. Gottesman,et al.  The endophenotype concept in psychiatry: etymology and strategic intentions. , 2003, The American journal of psychiatry.

[48]  Gert Lubec,et al.  Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders , 2003, Brain Research.

[49]  K. Lindpaintner,et al.  Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia , 2003, Amino Acids.

[50]  G. Lubec,et al.  Molecular changes in fetal Down syndrome brain , 2003, Journal of neurochemistry.

[51]  Akihiko Takashima,et al.  Presenilin-1 Mutation L271V Results in Altered Exon 8 Splicing and Alzheimer's Disease with Non-cored Plaques and No Neuritic Dystrophy* , 2003, The Journal of Biological Chemistry.

[52]  Gert Lubec,et al.  Proteomics in brain research: potentials and limitations , 2003, Progress in Neurobiology.

[53]  E. Lander,et al.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease , 2003, Nature Genetics.

[54]  M. Tabaton,et al.  Pure spastic paraparesis associated with a novel presenilin 1 R278K mutation , 2003, Neurology.

[55]  Pier Giorgio Righetti,et al.  Prefractionation techniques in proteome analysis , 2001, Proteomics.

[56]  S. Hanash.  Disease proteomics : Proteomics , 2003 .

[57]  Yong-Sun Kim,et al.  Identification of amyloid beta-peptide responsive genes by cDNA microarray technology: involvement of RTP801 in amyloid beta-peptide toxicity. , 2003, Experimental & molecular medicine.

[58]  M. Yaspo,et al.  Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: Challenging the gene dosage effect hypothesis (Part I) , 2003, Amino Acids.

[59]  S. Hanash,et al.  Disease proteomics , 2003, Nature.

[60]  H. Braak,et al.  Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. , 2003, Archives of neurology.

[61]  M. Ball,et al.  Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: Transcription and neurotrophic factor down‐regulation and up‐regulation of apoptotic and pro‐inflammatory signaling , 2002, Journal of neuroscience research.

[62]  T. Tabira,et al.  Alzheimer's disease with spastic paresis and cotton wool type plaques , 2002, Journal of neuroscience research.

[63]  T. Iwatsubo,et al.  Clinical and biomarker investigation of a patient with a novel presenilin-1 mutation (A431V) in the mild cognitive impairment stage of Alzheimer’s Disease , 2002, Biological Psychiatry.

[64]  J. Molinuevo,et al.  Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. , 2002, Archives of neurology.

[65]  C. V. van Duijn,et al.  A novel presenilin 1 mutation (L174 M) in a large Cuban family with early onset Alzheimer disease , 2002, Neurogenetics.

[66]  D. Butterfield,et al.  Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase‐related protein 2, α‐enolase and heat shock cognate 71 , 2002, Journal of neurochemistry.

[67]  N. Cairns,et al.  Human brain nucleoside diphosphate kinase activity is decreased in Alzheimer's disease and Down syndrome. , 2002, Biochemical and biophysical research communications.

[68]  D. Butterfield,et al.  Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. , 2002, Free radical biology & medicine.

[69]  B. Yoo,et al.  Expression patterns of antioxidant proteins in brains of patients with sporadic Creutzfeldt‐Jacob disease , 2002, Electrophoresis.

[70]  Nick C Fox,et al.  Early onset familial Alzheimer’s disease: Mutation frequency in 31 families , 2002 .

[71]  B. Reed,et al.  Very early‐onset familial Alzheimer's disease: a novel presenilin 1 mutation , 2002, International journal of geriatric psychiatry.

[72]  B. Ghetti,et al.  Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Aβ42 production , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[73]  J. Hardy,et al.  An Iranian family with Alzheimer's disease caused by a novel APP mutation (Thr714Ala). , 2002, Neurology.

[74]  G. Lubec,et al.  Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome , 2002, Neuroscience Letters.

[75]  B. Ghetti,et al.  A novel mutation (G217D) in the Presenilin 1 gene (PSEN1) in a Japanese family: presenile dementia and parkinsonism are associated with cotton wool plaques in the cortex and striatum , 2002, Acta Neuropathologica.

[76]  Kaj Blennow,et al.  Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients , 2002, Neuroreport.

[77]  R. Blesa,et al.  A novel mutation (V89L) in the presenilin 1 gene in a family with early onset Alzheimer's disease and marked behavioural disturbances , 2002, Journal of neurology, neurosurgery, and psychiatry.

[78]  M. Fountoulakis,et al.  Enrichment and proteomic analysis of low-abundance bacterial proteins. , 2002, Methods in enzymology.

[79]  D. Butterfield.  Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. , 2002, Free radical research.

[80]  M. Fountoulakis.  Proteomics: Current technologies and applications in neurological disorders and toxicology , 2001, Amino Acids.

[81]  M. Cruts,et al.  Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's disease due to a novel presenilin 1 mutation. , 2001, Brain : a journal of neurology.

[82]  R. J. Dolan,et al.  A novel presenilin mutation (M233V) causing very early onset Alzheimer's disease with Lewy bodies , 2001, Neuroscience Letters.

[83]  R. Simpson,et al.  Cancer proteomics: from signaling networks to tumor markers. , 2001, Trends in biotechnology.

[84]  C. van Broeckhoven,et al.  Systematic genetic study of Alzheimer disease in Latin America: mutation frequencies of the amyloid beta precursor protein and presenilin genes in Colombia. , 2001, American journal of medical genetics.

[85]  M. Yamada,et al.  Very early onset Alzheimer's disease with spastic paraparesis associated with a novel presenilin 1 mutation (Phe237Ile) , 2001, Journal of neurology, neurosurgery, and psychiatry.

[86]  G. Lubec,et al.  Brain α-endosulfine is manifold decreased in brains from patients with Alzheimer's disease: a tentative marker and drug target? , 2001, Neuroscience Letters.

[87]  You-Qiang Song,et al.  Screening for PS1 mutations in a referral-based series of AD cases , 2001, Neurology.

[88]  B. Strooper,et al.  Pathogenic APP mutations near the γ-secretase cleavage site differentially affect Aβ secretion and APP C-terminal fragment stability , 2001 .

[89]  Gert Lubec,et al.  Decreased brain levels of 2′,3′-cyclic nucleotide-3′-phosphodiesterase in Down syndrome and Alzheimer’s disease , 2001, Neurobiology of Aging.

[90]  N. Cairns,et al.  Brain t-complex polypeptide 1 (TCP- 1) related to its natural substrate beta1 tubulin is decreased in Alzheimer's disease. , 2001, Life sciences.

[91]  K Kosaka,et al.  Up-regulation of calcineurin Abeta mRNA in the Alzheimer's disease brain: assessment by cDNA microarray. , 2001, Biochemical and biophysical research communications.

[92]  T. Grabowski,et al.  Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy , 2001, Annals of neurology.

[93]  N. Cairns,et al.  Expression of apoptosis related proteins in brains of patients with Alzheimer's disease , 2001, Neuroscience Letters.

[94]  N. Cairns,et al.  The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease. , 2001, Life sciences.

[95]  S. Cordwell,et al.  Comparative proteomics of bacterial pathogens , 2001, Proteomics.

[96]  N. Cairns,et al.  Differential expression of molecular chaperones in brain of patients with Down syndrome , 2001, Electrophoresis.

[97]  N. Laird,et al.  The family based association test method: strategies for studying general genotype–phenotype associations , 2001, European Journal of Human Genetics.

[98]  N. Cairns,et al.  Synaptosomal Proteins, Beta-Soluble N-Ethylmaleimide-Sensitive Factor Attachment Protein (Beta-SNAP), Gamma-SNAP and Synaptotagmin I in Brain of Patients with Down Syndrome and Alzheimer’s Disease , 2001, Dementia and Geriatric Cognitive Disorders.

[99]  N. Cairns,et al.  Decreased brain histamine-releasing factor protein in patients with Down syndrome and Alzheimer's disease , 2001, Neuroscience Letters.

[100]  N. Cairns,et al.  Alteration of caspases and apoptosis-related proteins in brains of patients with Alzheimer's disease. , 2001, Biochemical and biophysical research communications.

[101]  A. Czernik,et al.  Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique , 2001, Neuroscience Letters.

[102]  F. Jessen,et al.  A family study of Alzheimer disease and early- and late-onset depression in elderly patients. , 2001, Archives of general psychiatry.

[103]  N. Cairns,et al.  Deranged expression of molecular chaperones in brains of patients with Alzheimer's disease. , 2001, Biochemical and biophysical research communications.

[104]  N. Cairns,et al.  Changes of voltage‐dependent anion‐selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down Syndrome , 2001, Electrophoresis.

[105]  N. Cairns,et al.  Superoxide Dismutase SOD1, Encoded on Chromosome 21, but Not SOD2 Is Overexpressed in Brains of Patients With Down Syndrome , 2001, Journal of Investigative Medicine.

[106]  N. Cairns,et al.  Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer's disease. , 2001, Journal of neural transmission. Supplementum.

[107]  N. Cairns,et al.  Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. , 2001, Journal of neural transmission. Supplementum.

[108]  B. de Strooper,et al.  Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. , 2001, Human molecular genetics.

[109]  N. Cairns,et al.  Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. , 2001, Journal of neural transmission. Supplementum.

[110]  A. Nairn,et al.  Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer's disease. , 2001, Journal of neural transmission. Supplementum.

[111]  N. Cairns,et al.  Neurofilament proteins NF-L, NF-M and NF-H in brain of patients with Down syndrome and Alzheimer's disease , 2001, Amino Acids.

[112]  G. Lubec.  Protein Expression in Down Syndrome Brain , 2001, Springer Vienna.

[113]  B. Nacmias,et al.  A presenilin-1 mutation (Leu392Pro) in a familial AD kindred with psychiatric symptoms at onset , 2000, Neurology.

[114]  D. Campion,et al.  Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation , 2000, Neurology.

[115]  H. Vanderstichele,et al.  Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. , 2000, Human molecular genetics.

[116]  A. Paetau,et al.  Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS‐1 mutations that lead to exceptionally high amyloid‐β concentrations , 2000, Annals of neurology.

[117]  N. Cairns,et al.  Decreased levels of complex III core protein 1 and complex V β chain in brains from patients with Alzheimer’s disease and Down syndrome , 2000, Cellular and Molecular Life Sciences CMLS.

[118]  P. S. St George-Hyslop,et al.  Novel presenilin 1 mutations associated with early onset of dementia in a family with both early-onset and late-onset Alzheimer disease. , 2000, Archives of neurology.

[119]  M. Gold,et al.  A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer’s disease , 2000, Neurology.

[120]  J. Trojanowski,et al.  Expression profile of transcripts in Alzheimer's disease tangle‐bearing CA1 neurons , 2000, Annals of neurology.

[121]  Eun Sug Park,et al.  Role of Peroxiredoxins in Regulating Intracellular Hydrogen Peroxide and Hydrogen Peroxide-induced Apoptosis in Thyroid Cells* , 2000, The Journal of Biological Chemistry.

[122]  H. Langen,et al.  Mass spectrometry: A tool for the identification of proteins separated by gels , 2000, Electrophoresis.

[123]  B. Ghetti,et al.  Early-onset Alzheimer disease caused by a new mutation (V717L) in the amyloid precursor protein gene. , 2000, Archives of neurology.

[124]  D. Butterfield,et al.  Oxidative Modification of Creatine Kinase BB in Alzheimer’s Disease Brain , 2000, Journal of neurochemistry.

[125]  Nick C Fox,et al.  Alzheimer's disease due to an intronic presenilin-1 (PSEN1 intron 4) mutation: A clinicopathological study. , 2000, Brain : a journal of neurology.

[126]  P. Cash.  Proteomics in medical microbiology , 2000, Electrophoresis.

[127]  C. Rohlff.  Proteomics in molecular medicine: Applications in central nervous systems disorders , 2000, Electrophoresis.

[128]  R. Blesa,et al.  A novel presenilin 1 mutation (Leu166Arg) associated with early-onset Alzheimer disease. , 2000, Archives of neurology.

[129]  P. Panegyres,et al.  Genetic testing for Alzheimer's disease , 2000, The Medical journal of Australia.

[130]  L. Murray,et al.  Association of interleukin‐1 gene polymorphisms with Alzheimer's disease , 2000, Annals of neurology.

[131]  Association of early‐onset Alzheimer's disease with an interleukin‐1α gene polymorphism , 2000, Annals of neurology.

[132]  Ellis Rj.  Moledular chaperones ten years. Introduction. , 2000 .

[133]  A. Tamaoka,et al.  Novel presenilin-1 mutation with widespread cortical amyloid deposition but limited cerebral amyloid angiopathy , 2000, Journal of neurology, neurosurgery, and psychiatry.

[134]  C. Masters,et al.  Novel Leu723Pro amyloid precursor protein mutation increases amyloid β42(43) peptide levels and induces apoptosis , 2000, Annals of neurology.

[135]  F. Hartl,et al.  Roles of molecular chaperones in cytoplasmic protein folding. , 2000, Seminars in cell & developmental biology.

[136]  R. Nitsch,et al.  High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. , 2000, American journal of human genetics.

[137]  D. Campion,et al.  A novel presenilin 1 missense mutation (L153V) segregating with early-onset autosomal dominant Alzheimer's disease. , 2000, Human mutation.

[138]  K. Roeder,et al.  Genomic Control for Association Studies , 1999, Biometrics.

[139]  M. Bullido,et al.  DGGE method for the mutational analysis of the coding and proximal promoter regions of the Alzheimer's disease presenilin‐1 gene: Two novel mutations , 1999, Human mutation.

[140]  B. Dubois,et al.  Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. , 1999, American journal of human genetics.

[141]  K. Kendler,et al.  Replication of linkage studies of complex traits: an examination of variation in location estimates. , 1999, American journal of human genetics.

[142]  P. Fraser,et al.  A presenilin-1 Thr116Asn substitution in a family with early-onset Alzheimer's disease. , 1999, Neuroreport.

[143]  R. Corbo,et al.  Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele? , 1999, Annals of human genetics.

[144]  J. Pritchard,et al.  Use of unlinked genetic markers to detect population stratification in association studies. , 1999, American journal of human genetics.

[145]  F. Jessen,et al.  A genetic variation of the inflammatory cytokine interleukin‐6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease , 1999, Annals of neurology.

[146]  D. Campion,et al.  Unusual phenotypic alteration of β amyloid precursor protein (βAPP) maturation by a new Val-715 → Met βAPP-770 mutation responsible for probable early-onset Alzheimer’s disease , 1999 .

[147]  E. Storey,et al.  Early-onset Alzheimer's disease caused by a novel mutation at codon 219 of the presenilin-1 gene. , 1999, Neuroreport.

[148]  R. Blesa,et al.  A presenilin 1 mutation (Ser169Pro) associated with early-onset AD and myoclonic seizures , 1999, Neurology.

[149]  Nick C Fox,et al.  Pathogenic presenilin 1 mutations (P436S & I143F) in early-onset Alzheimer's disease in the UK. Mutations in brief no. 223. Online. , 1999 .

[150]  Kyoko Suzuki,et al.  A novel missense mutation (G209R) in exon 8 of the presenilin 1 gene in a Japanese family with presenile familial Alzheimer's disease , 1999, Human mutation.

[151]  G. Sanders,et al.  Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease. , 1999, Genetic testing.

[152]  Gert Lubec,et al.  Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down Syndrome and Alzheimer's disease , 1999, Electrophoresis.

[153]  L. Lannfelt,et al.  A Polish pedigree with Alzheimer's disease determined by a novel mutation in exon 12 of the presenilin 1 gene: clinical and molecular characterization. , 1999, Folia neuropathologica.

[154]  N. Cairns,et al.  Increased levels of 14-3-3 gamma and epsilon proteins in brain of patients with Alzheimer's disease and Down syndrome. , 1999, Journal of neural transmission. Supplementum.

[155]  N. Cairns,et al.  Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. , 1999, Journal of neural transmission. Supplementum.

[156]  Nick C Fox,et al.  Pathogenic presenilin 1 mutations (P436S & I143F) in early‐onset Alzheimer's disease in the UK , 1999, Human mutation.

[157]  D. Campion,et al.  Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 --> Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[158]  G. Schellenberg,et al.  A pedigree with a novel presenilin 1 mutation at a residue that is not conserved in presenilin 2. , 1999, Archives of neurology.

[159]  R. Martins,et al.  Two novel presenilin‐1 mutations (Ser169Leu and Pro436Gln) associated with very early onset Alzheimer's disease , 1998, Neuroreport.

[160]  Takashi Asada,et al.  Familial Alzheimer's disease genes in Japanese , 1998, Journal of the Neurological Sciences.

[161]  L. Fernández-Novoa,et al.  A novel mutation in the predicted TM2 domain of the presenilin 2 gene in a Spanish patient with late-onset Alzheimer's disease , 1998, Neurogenetics.

[162]  Miguel Ángel Martínez,et al.  De novo presenilin 1 mutations are rare in clinically sporadic, early onset Alzheimer's disease cases. French Alzheimer's Disease Study Group. , 1998, Journal of medical genetics.

[163]  S. Antonarakis.  10 years of Genomics, chromosome 21, and Down syndrome. , 1998, Genomics.

[164]  L. Lannfelt,et al.  Wide range of disease onset in a family with Alzheimer disease and a His163Tyr mutation in the presenilin-1 gene. , 1998, Archives of Neurology.

[165]  A. Paetau,et al.  A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1 , 1998, Nature Medicine.

[166]  A. Brun,et al.  A 50-year perspective of a family with chromosome-14-linked Alzheimer’s disease , 1998, Human Genetics.

[167]  J. Buxbaum,et al.  A novel Polish presenilin‐1 mutation (P117L) is associated with familial Alzheimer's disease and leads to death as early as the age of 28 years , 1998, NeuroReport.

[168]  M. Bullido,et al.  Identification of a novel mutation (Leu282Arg) of the human presenilin 1 gene in Alzheimer's disease , 1998, Neuroscience Letters.

[169]  P. S. St George-Hyslop,et al.  A novel Leu171Pro mutation in presenilin-1 gene in a Mexican family with early onset Alzheimer disease. , 1998, Annales de genetique.

[170]  N. Cairns,et al.  A presenilin-1 truncating mutation is present in two cases with autopsy-confirmed early-onset Alzheimer disease. , 1998, American journal of human genetics.

[171]  C. van Broeckhoven,et al.  Presenilin mutations in Alzheimer's disease , 1998, Human mutation.

[172]  C. Broeckhoven,et al.  Missense mutation in exon 11 (codon 378) of the presenilin‐1 gene in a French family with early‐onset Alzheimer's disease and transmission study by mismatch enhanced allele specific amplification , 1998, Human mutation.

[173]  G. Schellenberg,et al.  Missense mutations in the chromosome 14 familial Alzheimer's disease presenilin 1 gene , 1998, Human mutation.

[174]  A Hofman,et al.  Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. , 1998, Human molecular genetics.

[175]  J. Hardy,et al.  A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). , 1997, Human molecular genetics.

[176]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[177]  Lars Lannfelt,et al.  A novel pathogenic mutation (Leu262Phe) found in the presenilin 1 gene in early-onset Alzheimer's disease , 1997, Neuroscience Letters.

[178]  Y. Ikejiri,et al.  A novel missense mutation in the presenilin-1 gene in a familial Alzheimer's disease pedigree with abundant amyloid angiopathy , 1997, Neuroscience Letters.

[179]  L. Thal,et al.  Early‐onset Alzheimer's disease with a presenilin‐1 mutation at the site corresponding to the volga German presenilin‐2 mutation , 1997, Annals of neurology.

[180]  J. Growdon,et al.  A novel presenilin‐1 mutation: Increased β‐amyloid and neurofibrillary changes , 1997 .

[181]  J. Hardy,et al.  Two novel (M233T and ρ278T) presenilin‐1 mutations in early‐onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin‐1 mutations with a novel phenotype , 1997, Neuroreport.

[182]  K Johansson,et al.  Heritability for Alzheimer's disease: the study of dementia in Swedish twins. , 1997, The journals of gerontology. Series A, Biological sciences and medical sciences.

[183]  M McNamara,et al.  A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes. , 1997, Annals of neurology.

[184]  A D Roses,et al.  Apolipoprotein E and Alzheimer's Disease A Rapidly Expanding Field with Medical and Epidemiological Consequences , 1996, Annals of the New York Academy of Sciences.

[185]  J. Aharon-Peretz,et al.  A novel mutation of presenilin 1 in familial Alzheimer’s disease in Israel detected by denaturing gradient gel electrophoresis , 1996, Human Genetics.

[186]  A. L. Jørgensen,et al.  Familial Alzheimer's disease co‐segregates with a Met 146 Ile substitution in presenilin‐1 , 1996 .

[187]  N Risch,et al.  The Future of Genetic Studies of Complex Human Diseases , 1996, Science.

[188]  J. Hardy,et al.  A further presenilin 1 mutation in the exon 8 cluster in familial Alzheimer's disease. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[189]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[190]  Nick C Fox,et al.  Incomplete penetrance of familial Alzheimer's disease in a pedigree with a novel presenilin-1 gene mutation , 1996, The Lancet.

[191]  T. Ogihara,et al.  Three different mutations of presenilin 1 gene in early-onset Alzheimer's disease families , 1996, Neuroscience Letters.

[192]  W. Tsai,et al.  Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. , 1996, American journal of human genetics.

[193]  M. Adams,et al.  Complete analysis of the presenilin 1 gene in early onset Alzheimer's disease , 1996, Neuroreport.

[194]  J. Gilbert,et al.  Mutation analysis of presenilin 1 gene in Alzheimer's disease , 1996, The Lancet.

[195]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.

[196]  J. Gilbert,et al.  Mutation analysis of presenillin 1 gene in Alzheimer's disease. , 1996, Lancet.

[197]  S. Gauthier,et al.  Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[198]  M. Adams,et al.  A mutation in Alzheimer's disease destroying a splice acceptor site in the presenilin-1 gene , 1995, Neuroreport.

[199]  B. Dubois,et al.  Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. , 1995, Human molecular genetics.

[200]  M. Cruts,et al.  Molecular genetic analysis of familial early-onset Alzheimer's disease linked to chromosome 14q24.3. , 1995, Human molecular genetics.

[201]  G. Schellenberg,et al.  Apolipoprotein E genotypes and age of onset in early‐onset familial Alzheimer's disease , 1995, Annals of neurology.

[202]  O. Gureje,et al.  Lack of an association between apolipoprotein E ϵ4 and Alzheimer's disease in elderly nigerians , 1995 .

[203]  J. Growdon,et al.  Familial Alzheimer's chromosome 14 mutations , 1995, Nature Medicine.

[204]  J. Rommens,et al.  Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene , 1995, Nature.

[205]  E M Wijsman,et al.  A familial Alzheimer's disease locus on chromosome 1 , 1995, Science.

[206]  R. Sherrington,et al.  Misserise mutation of S182 gene in Italian families with early-onset Alzheimer's disease , 1995, The Lancet.

[207]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[208]  R. Frackowiak,et al.  Chromosome 14 linked familial Alzheimer's disease. A clinico-pathological study of a single pedigree. , 1995, Brain : a journal of neurology.

[209]  Y. Agid,et al.  A large pedigree with early-onset Alzheimer's disease , 1995, Neurology.

[210]  O. Gureje,et al.  Lack of an association between apolipoprotein E epsilon 4 and Alzheimer's disease in elderly Nigerians. , 1995, Annals of neurology.

[211]  R. Sherrington,et al.  Missense mutation of S182 gene in Italian families with early-onset Alzheimer's disease. , 1995, Lancet.

[212]  M. Adams,et al.  The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families , 1995, Nature Genetics.

[213]  S. M. Sumi,et al.  Phenotype of chromosome 14–linked familial Alzheimer's disease in a large kindred , 1994, Annals of neurology.

[214]  L. Wilkins.  Guidelines for the molecular genetics predictive test in Huntington's disease , 1994, Neurology.

[215]  K. Davis,et al.  Patterns of risk in first-degree relatives of patients with Alzheimer's disease. , 1994, Archives of general psychiatry.

[216]  C. Clark,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1994, Neurology.

[217]  Anthony F Jorm,et al.  Assessing the risk of Alzheimer's disease in first-degree relatives of Alzheimer's disease cases , 1993, Psychological Medicine.

[218]  S. Gauthier,et al.  Apolipoprotein E polymorphism and Alzheimer's disease , 1993, The Lancet.

[219]  M A Pericak-Vance,et al.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. , 1993, Neurology.

[220]  E. Wijsman,et al.  Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. , 1992, American journal of human genetics.

[221]  J. Weber,et al.  Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. , 1992, Science.

[222]  B. Winblad,et al.  A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid , 1992, Nature Genetics.

[223]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[224]  A. Hofman,et al.  Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β–amyloid precursor protein gene , 1992, Nature Genetics.

[225]  J. Hardy,et al.  Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene , 1991, Nature.

[226]  B. Ghetti,et al.  A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. , 1991, Science.

[227]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[228]  I. Lieberburg,et al.  Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. , 1990, Science.

[229]  M. Albert,et al.  Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.

[230]  J. Growdon,et al.  Assessment of genetic risk for alzheimer's disease among first‐degree relatives , 1989, Annals of neurology.

[231]  A. Chakravarti,et al.  Risk of dementia in relatives of patients with Alzheimer's disease , 1988, Neurology.

[232]  S. M. Sumi,et al.  Familial alzheimer's disease in american descendants of the volga germans: Probable genetic founder effect , 1988, Annals of neurology.

[233]  D. Pollen,et al.  The genetic defect causing familial Alzheimer's disease maps on chromosome 21. , 1987, Science.

[234]  P. S. St George-Hyslop,et al.  Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. , 1987, Science.

[235]  M. Folstein,et al.  Familial aggregation in Alzheimer dementia--I. A model for the age-dependent expression of an autosomal dominant gene. , 1986, Journal of psychiatric research.

[236]  M. Folstein,et al.  Familial Alzheimer Dementia: a prevalent disorder with specific clinical features , 1984, Psychological Medicine.

[237]  Michael Swift,et al.  Alzheimer's disease: Genetic aspects and associated clinical disorders , 1983, Annals of neurology.

[238]  C. Glueck,et al.  Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. , 1982, Journal of lipid research.

[239]  V. Anderson,et al.  Dementia of the Alzheimer Type: Clinical Genetics, Natural History, and Associated Conditions , 1981 .

[240]  P. O’Farrell.  High resolution two-dimensional electrophoresis of proteins. , 1975, The Journal of biological chemistry.